N-Acetyl Selank is a synthetic peptide, an acetylated form of Selank in which a two-carbon acetyl group caps the N-terminus to slow enzymatic breakdown. It is sold as a research chemical rather than an approved medicine, and it is not an approved drug in the United States. Direct human evidence for the acetylated molecule is thin, and nearly all of its reported anxiolytic and nootropic properties are extrapolated from studies of plain Selank rather than demonstrated for the modified form.
N-Acetyl Selank is an acetylated, degradation-resistant form of the synthetic peptide Selank that circulates as an unapproved research chemical in the United States, with its anxiolytic and nootropic claims drawn from Selank studies rather than demonstrated for the modified molecule.
The only deliberate difference between the two molecules is a single acetyl cap: N-Acetyl Selank is Selank with a two-carbon acetyl group bonded to the free amino group at the N-terminus. Selank itself is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences by extending the endogenous immune tetrapeptide tuftsin with a Pro-Gly-Pro tail. The record describes the acetylated variant as a more degradation-resistant version of the same peptide, not a different molecule with a different intended effect.
| Property | Selank | N-Acetyl Selank |
|---|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro heptapeptide | Same sequence, acetyl cap at N-terminus |
| Design goal | Stabilized tuftsin extension | Further resistance to aminopeptidase cleavage |
| Origin | Fully synthetic; only the tuftsin fragment is endogenous | Fully synthetic derivative of Selank |
| Intended effect | Anxiolytic, nootropic | The same, assumed by analogy |
N-Acetyl Selank differs from Selank only by an acetyl group added to the N-terminus, a modification intended to resist aminopeptidase cleavage while keeping the same tuftsin-derived heptapeptide sequence and the same intended anxiolytic and nootropic use.
The proposed pharmacology comes almost entirely from Selank, since the acetyl cap is meant to change durability rather than mechanism. The literature describes the peptide acting on several systems at once rather than through a single receptor, which is the leading explanation offered for a calming effect that reportedly lacks the sedation of classic anti-anxiety drugs.
N-Acetyl Selank is proposed to work through Selank's multi-target profile, modulating serotonin and dopamine, altering BDNF expression in animal models, interacting with the enkephalin system, and carrying tuftsin-derived immunomodulatory activity, rather than acting on any single receptor.
The headline attribution is anxiolysis paired with a claim that sets the peptide apart: relief from anxiety without the sedation, cognitive dulling, dependence, or withdrawal linked to benzodiazepines. Most of these effects are documented for Selank rather than the acetylated form, and many of the sharper performance claims originate with vendors rather than controlled human trials.
The effects attributed to N-Acetyl Selank, anxiolysis without sedation plus mild gains in memory, attention, and stress resilience, are partly supported for Selank and assumed for the acetylated form by analogy, with real-world magnitude in humans far less established than marketing language implies.
The evidence base splits in two, and the split is the whole story: nearly all of the research concerns Selank, while published human data on N-Acetyl Selank specifically is close to nonexistent. For Selank there is a real body of rodent work plus a smaller set of human clinical studies, several conducted in Russia, reporting anxiolytic activity in generalized anxiety disorder with a favorable tolerability profile. For the acetylated variant, efficacy is inferred from that Selank record rather than independently demonstrated.
| Evidence dimension | Selank | N-Acetyl Selank |
|---|---|---|
| Preclinical (animal) | Substantial rodent literature | Essentially none specific to the acetylated form |
| Human clinical | Small set, several Russian GAD studies | Close to nonexistent in peer-reviewed form |
| Independent replication | Limited, concentrated in originating institutions | Not established |
| Overall standing | Suggestive, not definitive | Substantially less studied than Selank |
Published human evidence for N-Acetyl Selank specifically is close to nonexistent, and its support is inferred from a Selank literature that is itself suggestive rather than definitive and concentrated in the Russian institutions that developed the peptide.
In the research-chemical world the acetylated peptide is handled much like Selank, with intranasal delivery reported as the most common route by a wide margin and subcutaneous injection as the secondary one. The nasal route is favored in the literature because peptides are poorly absorbed and rapidly digested when swallowed, and because the nasal mucosa is thought to offer a more direct path toward the central nervous system. No approved human dosing regimen exists, and the figures below describe how the compound is handled in a research context rather than any recommended use.
In research settings N-Acetyl Selank is most often delivered intranasally, reconstituted from lyophilized powder with bacteriostatic water, with reported figures for Selank-type peptides of a few hundred to roughly nine hundred micrograms per day drawn from vendor protocols rather than any approved human dosing standard.
Selank carries a reputation for being well tolerated and the same is generally assumed for the acetylated form, but that reassurance rests on limited data and reads better as a caution than a clearance. The reported side effects are mild and short-lived, yet the larger issue is the near-total absence of long-term human data for the acetylated molecule, compounded by the quality risks of a product sold outside pharmaceutical control.
Reported side effects of N-Acetyl Selank are mild and short-lived, but long-term human safety for the acetylated form is unestablished, and research-chemical sourcing adds real uncertainty over purity, identity, dose accuracy, and sterility independent of the peptide's own pharmacology.
In the United States N-Acetyl Selank is not an approved drug, not an approved dietary-supplement ingredient, and has not been evaluated by the FDA for safety or efficacy, which is why it ships under research-use-only or not-for-human-consumption labeling. That labeling is a legal boundary rather than a formality: it permits sale for laboratory purposes while placing responsibility on the buyer and not authorizing human use.
N-Acetyl Selank is not FDA-approved as a drug or supplement in the United States and is sold only under research-use-only labeling, its status abroad does not transfer between countries, and it can trigger anti-doping violations in competitive sport as a non-approved substance.
The entire rationale for the acetylated form rests on chemistry at the N-terminus. Aminopeptidases attack peptides by chewing inward from the free amino group at that terminus, and capping it with an acetyl group removes the exact chemical handle those enzymes recognize, so the modified peptide is expected to survive longer in solution and, in theory, in the body.
N-acetylation is expected to extend Selank's half-life and shelf stability by blocking aminopeptidase cleavage at the N-terminus, but the magnitude of that gain, its effect on intranasal absorption, and confirmation that potency is fully preserved remain vendor-asserted rather than proven in peer-reviewed studies of the acetylated form.
Selank and Semax are usually discussed as a pair because both are synthetic Russian-developed regulatory peptides pursued for cognitive and mental-health uses, but they trace to different parent molecules and lean in different directions. Semax derives from a fragment of the hormone ACTH rather than from tuftsin, and the record casts it as the more stimulating, focus-and-drive peptide, while Selank and by extension N-Acetyl Selank is the calmer counterpart weighted toward anxiolysis and stress buffering.
| Dimension | N-Acetyl Selank (Selank family) | Semax family |
|---|---|---|
| Parent molecule | Tuftsin-derived heptapeptide | Fragment of ACTH |
| Reported lean | Anxiolysis, stress buffering, mood stability | Stimulation, focus, drive, neuroprotection |
| Key mechanism cited | Monoamine and enkephalin modulation | BDNF and nerve growth factor |
| Acetylated analog | N-Acetyl Selank | N-Acetyl Semax |
Within the Russian regulatory-peptide family, Selank and its N-acetyl form lean toward anxiolysis and stress buffering while the ACTH-derived Semax family leans toward focus and drive, and both exist in acetylated, degradation-resistant forms under the same unapproved-status and thin-human-evidence caveats.
Educational use only. This article describes what the published scientific and clinical literature reports about N-Acetyl Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
